It has been proposed that thymosin beta 4 (TB4)-protein delivery stimulates differentiation of resident adult WT1-positive cardiac progenitor cells, but with very low efficiency. We determined whether gene therapy with human TB4 stimulates proliferation of resident adult cardiac progenitor cells in normal rat heart. Ultrasound-targeted microbubble destruction (UTMD) was used to deliver the human TB4 gene under a piggybac transposon plasmid to normal rat heart. The rat hearts were assayed by quantitative reverse transcription-PCR and immunohistology with a confocal microscope at 1, 2, 3, 4 and 12 weeks after UTMD. Exogenous TB4 stimulation resulted in the presence of WT1-positive cardiac progenitor cells from epicardium to endocardium. TB4 stimulated angiogenesis and arteriogenesis. One month after TB4 gene therapy by UTMD, the percentage of NKX2.5-positive cardiomyocytes was 5.5±1.0% and NKX2.5 mRNA was 24-fold higher than in the control groups (Po0.001). Similar results were found for ISL-1, BrDu, Ki-67, PHH3 and aurora B (Po0.001). Cardiac-specific delivery of exogenous human TB4 gene efficiently stimulates proliferation and differentiation of resident WT1-positive adult cardiac progenitor cells into three intact cardiac cell lineages-vascular endothelial cells, coronary artery smooth muscle cells and cardiac muscle cells in normal adult rat heart.
INTRODUCTION
It is estimated that acute myocardial infarction afflicts 1.3 million Americans every year. 1 Approximately 10% of those patients will die from the myocardial infarction, typically from ventricular arrhythmias, pump failure or myocardial rupture. In survivors, infarcted myocardium is replaced by fibrous scar tissue, leading to progressive left ventricular (LV) remodeling and congestive heart failure. Although prompt revascularization of the occluded coronary artery by percutaneous coronary intervention has been shown to reduce mortality, the myocardial microcirculation may not be completely reperfused due to the 'no-reflow' phenomenon, and some degree of myocardial necrosis typically remains. Therefore, a major goal of therapy for acute myocardial infarction has been to develop strategies for regeneration of cardiomyocytes and blood vessels in the damaged area of the heart. Novel strategies for myocardial regeneration include cell therapy with embryonic stem cells, iPS cells and bone marrow stem cells. [2] [3] [4] Recently, resident cardiac progenitor cells were discovered in the adult mammalian heart. Although sparse in number, these cells are self-renewing, clonogenic and multipotent. Theoretically, they can differentiate into all three major cardiac lineages-vascular smooth muscle cells, endothelial cells and cardiac muscle cells. [5] [6] [7] [8] [9] [10] However, it remains controversial whether adult cardiac muscle cells can be formed from these resident progenitor cells in vivo.
The purpose of this study was to deliver thymosin beta 4 (TB4) gene directly to the heart of normal rats, in order to stimulate resident cardiac progenitor cells. We employed ultrasoundtargeted microbubble destruction (UTMD), [11] [12] [13] [14] [15] [16] [17] [18] which has been used to direct gene or protein therapy to the heart in vivo. UTMD was used to deliver the human TB4 gene under a piggybac transposon plasmid system [19] [20] [21] [22] [23] to normal rat hearts. After a single UTMD treatment, transgenic overexpression of TB4 in rat heart tissue was observed for three months with evidence that adult cardiac progenitor cells proliferated and differentiated into three intact cardiac cell lineages-vascular endothelial cells, coronary artery smooth muscle cells and cardiomyocytes.
RESULTS
Overexpression of exogenous human TB4 for 12 weeks and activation of WT1-positive progenitor cells Figure 1 shows weak endogenous TB4 signal at the epicardial layer of normal control and UTMD-DsRed control hearts euthanized at one month. After exogenous TB4 gene delivery by UTMD, a strong exogenous transmural TB4 signal was observed throughout the heart from epicardium to endocardium, indicating robust TB4 transgene expression by UTMD. Quantitative reverse transcription-PCR (qRT-PCR) shows that the human TB4 mRNA level in UTMD-TB4 groups was 72-fold at 1 week, 74-fold at 2 weeks, 67-fold at 3 weeks, 52-fold at 4 weeks and 46-fold at 12 weeks after UTMD treatment greater than in normal control or UTMD-DsRed control groups (Po0.001). Routine RT-PCR showed that low level of endogenous rat TB4 did not interfere with overexpression of exogenous human TB4. Transgenic expression of reporter gene DsRed also indicated a cardiac location of human TB4. Supplementary Figure S1 shown that DsRed durably expressed for three months after single UTMDDsRed procedure.
WT1 is a biomarker for development of embryonic heart and is not normally expressed in adult rat heart. Figure 2 shows that one week after UTMD-TB4 treatment WT1 started to express from the nucleus of epicardium layer cells. More interestingly these WT1-positive cardiac progenitor cells were observed in the mid-myocardium layer and formed new cardiac muscle cells (WT1 nuclear signal from cTnT-positive cells in myocardium layer) in the 4th week after TB4 gene therapy. WT1 mRNA level in UTMD-TB4 group was 43.5-fold higher than in normal control or UTMD-DsRed groups at 4 weeks after UTMD-TB4 treatment (Po0.001) (Supplementary Figure S2A) . c-kit is a marker of adult cardiac progenitor cells. Figures 5d-f shown that c-kit-positive cells are in proliferation, c-kit mRNA level in UTMD-TB4 group was 52-fold higher than in normal control or UTMD-DsRed groups at 4 weeks after UTMD-TB4 treatment (Po0.001) (Supplementary Figure S2B ).
TB4 induces angiogenesis and arteriogenesis
Previous reports indicated that TB4 stimulates angiogenesis and coronary arteriogenesis in adult hearts. Figure 3 shows evidence that coronary artery density significantly increases in UTMD-TB4 treatment groups 1-12 weeks after UTMD treatment (Po0.001). Smooth muscle a-actin mRNA level was 11.9-fold higher in the UTMD-TB4 groups than in the two control groups (Po0.01) (Supplementary Figure S2D) . Capillary density was also significantly increased in UTMD-TB4 treatment groups 1-12 weeks after UTMD treatment (Po0.001). Vascular endothelial growth factor mRNA level in UTMD-TB4 treatment group was 9.9-fold higher than in control groups (Po0.01) (Supplementary Figure S2C) . Tie-2 mRNA and PECAM mRNA level in UTMD-TB4 treatment group were significantly increased relative to controls (data not shown).
Evidence of new cardiomyocyte differentiation NKX2.5-positive cardiomyocytes are considered precursors of mature cardiomyocytes, or as cardiac muscle progenitor cells undergoing differentiation.
8 Figure 4 shows the presence of NKX2.5-positive adult cardiomyocytes in the UTMD-TB4 treatment group, but not in the controls. NKX2.5 signal was clearly seen in the nucleus of a small number of cardiac troponin T-positive cells. We calculated the percentage of NKX2.5-or ISL-1-positive cardiomyocytes by counting NKX2.5 or ISL-1-positive nucleus (pink color) from 2000 cTnT-positive cardiomyocytes cells in LV anterior and posterior wall with serial sections through each rat heart (n ¼ 6 each group, mean±s.e.m.). The lower right panel of Figure 4 shows that the percentage of NKX2.5-positive cardiomyocytes in UTMD-TB4 groups were 3.6 ± 0.8% at 1 week, 3.7±0.4% at 2 weeks, 4.6±0.4% at 3 weeks, 5.5±1.0% at 4 weeks and 3.9 ± 0.7% at 12 weeks after UTMD treatment (Po0.001 vs controls). The left lower panel of Figure 4 shows that qRT-PCR for NKX2.5 mRNA in UTMD-TB4 treatment groups was 10.7-fold at 1 week, 20-fold at 2 weeks, 20.7-fold at 3 weeks, 24-fold at 4 weeks and 15.6-fold at 12 weeks after UTMD treatment relative to normal control or UTMD-DsRed control groups (Po0.001). ISL-1-positive cardiomyocytes have been previously defined as precursor cells of mature cardiomyocytes, or as cardiac muscle progenitor cells undergoing differentiation. Evidence of self-renewal or proliferation of new cardiomyocytes We decided to investigate if these new cardiac muscle cells are proliferating or self-renewing by using two proliferation markers (anti-BrDu and anti-Ki-67) and two mitotic markers (anti-phosphohistone H3 (Ser10) (PHH3) and anti-aurora B). We calculated the percentage of BrDu, PHH3 or Ki-67 or aurora B-positive cardiomyocytes by counting nuclei (pink color) from 2000 cTnTpositive cardiomyocytes cells in LV anterior and posterior wall with serial sections through each rat heart (n ¼ 6 each group, ±s.e.m.). Figure 6 and Supplementary Figures S3G-I shown that BrDu signal was observed within the nucleus of cTnT-positive cardiomyocytes by confocal microscopy. The percentage of BrDu-positive cardiac muscle cells in UTMD-TB4 treatment group was 3.4±0.8% at 1 week, 3.4 ± 0.5% at 2 weeks, 4.8 ± 0.2% at 3 weeks, 5.7 ± 0.5% at 4 weeks and 3.83 ± 0.41% at 12 weeks after UTMD treatment (Po0.001 vs controls). Figure 6 and Supplementary Figures S3D-F show Ki-67 signal within the nucleus of cTnT-positive cardiomyocytes by confocal microscopy. The percentage of Ki-67-positive cardiac muscle cells in UTMD-TB4 treatment group was 3.1 ± 0.8% at 1 week, 3.6±0.5% at 2 weeks, 4.5±0.9% at 3 weeks, 5.7±0.3% at 4 weeks and at 4.1 ± 0.4% at 12 weeks after UTMD (Po0.001 vs controls). Figure 7 and Supplementary Figures S3A-C show PHH3 signal within the nucleus of cTnT-positive cardiomyocytes by confocal microscopy. The percentage of PHH3-positive cardiac muscle cells in UTMD-TB4 treatment group was 3.9 ± 0.5% at 1 week, 4.5 ± 0.5% at 2 weeks, 5.1 ± 1.0% at 3 weeks, 6.8 ± 1.0% at 4 weeks and 4.2±0.3% at 12 weeks after UTMD treatment (Po0.001 vs controls). The percentage of aurora B-positive cardiac muscle cells in UTMD-TB4 treatment group was 3.5 ± 0.9% at 1 week, 3.8 ± 1.2% at 2 weeks, 5.2 ± 0.7% at 3 weeks, 5.7 ± 0.3% at 4 weeks and 4.1±0.5% at 12 weeks after UTMD treatment (Po0.001 vs controls). Aurora B staining also displayed different stages of mitosis activity of new cardiomyocytes ( Figure 7 and Supplementary Figures S3J-L) . Supplementary Figure S4 shown that there have not seen significant change between LV fractional shortening and LV posterior wall dimensions in treated vs control animals. DISCUSSION TB4, a 43-amino-acid G-actin-sequestering peptide, shows a wide range of effects when systemically administered to animals, including the promotion of cell migration, blood vessel formation, cell survival, stem cell differentiation and the modulation of cytokines. Using cell-lineage tracing, it has been reported that TB4 activates resident WT1-positive epicardial progenitor cells that migrate to the ischemic area and differentiate into coronary vascular cells, endothelial cells and cardiomyocytes in ischemic mouse hearts. [24] [25] [26] However, Pu and coworkers 27 reported different results that TB4 treatment after experimental myocardial infarction does not reprogram epicardial cells into cardiomyocytes. In addition, TB4 protein treatment has not been previously shown to stimulate cardiomyocyte regeneration in normal heart. It is likely that the disparity in these results is partly methodological. For example, a once-daily intraperitoneal injection of TB4 protein for consecutive 6 days may not maintain TB4 at a stable effective blood concentration, especially as its half-life is very short (1.8-2.1 h). In addition, systemic administration of TB4 may cause side effects in other organs. An advantage of this study is the use of a targeted delivery approach resulting in durable TB4 treatment throughout the myocardium. We combined the use of two novel technologies for Stimulation of adult resident cardiac progenitor cells S Chen et al gene delivery, UTMD and the piggybac transposon system, to achieve longer-term gene expression because we hypothesized that adult cardiac progenitor cells need durable TB4 stimulation to complete their differentiation. UTMD has been used to achieve organ-specific delivery of adenovirus, plasmids and protein to heart, pancreas, skeletal muscle and other organs. [11] [12] [13] The payload is attached to microbubbles, which are administered intravenously and circulate freely throughout the body. Ultrasound is used to destroy the microbubbles within the microcirculation of the target organ. This process results in penetration of cells membranes by a reversible process termed 'sonoporation'. 28 Although toxicity is possible with a combination of high dose microbubbles, and low transmit frequency and/or high power ultrasound settings, we used microbubble dosing and ultrasound settings that have been optimized for successful gene delivery without evidence of myocardial necrosis or inflammation.
11,12
The piggybac transposon gene-delivery system integrates donor genes into host cell genomic DNA via a simple 'cut and paste' mechanism. This system has been used to achieve long-term transgene expression in rat pancreas 19 and mouse liver. 20 We also used a human TB4 complementary DNA (cDNA) to try to distinguish the effect of the exogenous delivered transgene from endogenous TB4. To our knowledge, this is the first paper to apply piggybac transposon gene-delivery system to the heart, and the first to achieve cardiac-specific durable TB4 gene therapy lasting for 3 months. The epicardium is a single layer of quiescent epithelial cells located at the surface of the myocardium layer that does not express WT1. One week after UTMD-TB4 WT1 is activated and expressed in the epicardial cells. Previous studies have shown that TB4 stimulates epicardiumderived cells to undergo epithelial to mesenchymal transformation to form WT1-positive cardiac progenitor cells and then migrate into the myocardium prior to differentiation. 29 Our studies are consistent with this concept in that we found cells expressing TB4, WT1 and c-kit within the endocardium, midmyocardium and epicardium in normal heart after UTMD gene therapy with human TB4. Using cell-lineage tracking, previous investigators have shown that epicardium-derived cells stimulated by systemic administration of TB4 protein migrated from the epicardium, and exhibited characteristics of cardiac progenitor cells. 8 Our study does not allow us to rule out the possibility that TB4 stimulated other cardiac cell types because our UTMD technique transfects existing cells throughout the heart. Smart et al. 8 reported low efficiency of TB4 protein treatment (0.59 ± 0.18% de novo cardiomyocytes) in the ischemic area, which was deemed too low to achieve 'any therapeutic effects.' In contrast, Song et al. 30 reported 6.5% of new cardiac muscle cells were formed after retroviral GATA4, Hand2, MEF2C and TBX5 genes local injected in ischemic area. We found a similar average of 5.5% new cardiac muscle cells in normal heart with UTMD-TB4 plasmids gene therapy. Based on our experiment results, we think three weeks may not be long enough for adult WT1 progenitor cells to differentiate into cardiac muscle cells (Figure 2) . We evaluated the efficiency of the myocardial differentiation with myocardial differentiation markers (NKX2.5 and ISL-1), mitosis markers (phospho-histone H3, aurora B) and proliferation markers (BrDu and KI-67). Our results show that after 3 months of TB4 gene therapy, there was a roughly 5-10-fold higher number of new cardiomyocytes compared with the Riley study. We believe that this higher efficiency is likely due to the robust and durable expression of TB4 gene after UTMD therapy using the piggybac transposon system targeting to heart 
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as compared with systemic administration of TB4 protein therapy or plus endogenous TB4 induced by acute ischemic heart injury. We also think that the possibility on the self-duplication of adult cardiomyocytes induced by TB4 is unlikely because of co-expression of both NKX2.5 and ISL-1 within cardiomyocytes. Likewise, the finding of BrDu, Ki-67, PHH3 or aurora B within cardiomyocytes indicates proliferation, rather than hypertrophy. Dedifferentiation and proliferation of mature cardiomyocytes has only been observed in zebrafish, amphibians 31 or in neonatal mouse heart. 32 However, in our study we did not observe this phenomenon of sarcomere disassembly in PHH3-positive cardiomyocytes. So we excluded the possibility of the dedifferentiation and proliferation of mature cardiomyocytes induced by TB4 gene therapy. In the absence of endogenous TB4 induced by acute ischemia, cardiac-specific delivery of exogenous human TB4 gene efficiently stimulates differentiation of resident WT1-positive adult cardiac progenitor cells into three intact cardiac cell lineages-vascular endothelial cells, coronary artery smooth muscle cells and cardiac muscle cells in normal adult rat heart. Further studies are needed in an ischemic model to determine if gene therapy with TB4 using this methodology is able to prevent myocardial remodeling and/or achieve significant myocardial regeneration. For this study, we deliberately chose to use normal rat hearts to avoid the possible confounding from endogenous TB4 induced by ischemia.
MATERIALS AND METHODS

Animal protocols and UTMD
All animal studies were performed in accordance with National Institute of Health (NIH) recommendations and the approval of our institutional animal research committee. Male Sprague-Dawley rats (230-270 g) were anesthetized with intraperitoneal ketamine (60 mg kg À 1 ) and xylazine (5 mg kg À 1 ) and a polyethylene tube (PE 50, Becton Dickinson, Franklin Lakes, TN, USA) was inserted into the right internal jugular vein by cut-down.
Animal protocol-1: a total of 36 rats received one of three treatments: (1) no treatment (normal control rats, n ¼ 12); (2) UTMD with pXL-BASII-CIDsRed/pCI-mPB (n ¼ 12); (3) UTMD with pXL-BASII-CI-TB4/pCI-mPB (n ¼ 12), all were killed at 4 weeks after UTMD.
Animal protocol-2: a time-course experiment for BrDU incorporation. A total of 90 rats received one of three treatments: (1) no treatment (normal control rats, n ¼ 6); (2) UTMD with pXL-BASII-CIDsRed/pCI-mPB (n ¼ 6); (3) UTMD with pXL-BASII-CI-TB4/pCI-mPB (n ¼ 6), were killed at 1 week, 2 weeks, 3 weeks, 4 weeks and 12 weeks after UTMD. The thymidine analog, 5-bromo-2-deoxyuridine (BrdU) (100 mg kg À 1 , Sigma, St Louis, MO, USA) intraperitoneal injected 6 h prior to killing.
Piggybac transposon donor plasmids and helper plasmids ratio (pXL-BASII-CI-TB4/pCI-mPB) was 5:1. Microbubble or control solutions (0.5 ml diluted with 0.5 ml phosphate-buffered saline (PBS)) were infused over 5 min via pump (Genie, Kent Scientific, Torrington, CT). During the infusion, ultrasound was directed to the heart using a commercially available ultrasound transducer (S3, Sonos 5500, Philips Ultrasound, Bothell, WA, USA). The probe was clamped in place. Ultrasound was then applied in ultraharmonic mode (transmit 1.3 MHz/receive 3.6 MHz) at a mechanical index of 1.4. Four bursts of ultrasound were triggered to every fourth end-systole by electrocardiogram using a delay of 45-70 ms after the peak of the R wave. These settings have shown to be optimal for plasmid delivery by UTMD using this instrument (11) . Bubble destruction was visually apparent in all rats. After UTMD, the jugular vein was tied off, the skin closed, and the animals allowed to recover. All of rats were euthanized using an overdose of sodium pentobarbital (120 mg kg À 1 ). Heart, pancreas, liver, spleen and kidney were harvested for histology and qRT-PCR assay. Total RNA was isolated from 100 mg of harvested heart using the Trizol reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions and reverse-transcribed using Superscript III RT (Invitrogen). Real-time RT-qPCR analysis was performed on an ABI 7700 Sequence Detector (Applied Biosystems, Carlsbad, CA, USA) using SYBR Green (RT 2 SYBR Green qPCR Kit, Qiagen, Valencia, CA, USA). Data were normalized to HKG expression (endogenous control). Changes in gene expression were normalized to control rat heart tissue. Complementary DNA PCR primer sequences information should be requested to the correspondence author.
Capillary and arteriolar density measurement Intra-insular CD31-positive vessels with diameter f 10 mm and smooth muscle a-actin-positive vessels with a diameter of 430 mm visualized by immunohistochemistry were considered as capillaries and arterioles, respectively. Capillaries were counted by the use of fluorescence microscopy at a magnification of Â 200. Five photomicrographs were taken from each slide and a grid was placed over each photomicrograph. Using a random number generator, five sections from each grid were selected for counting, giving a total of 25 fields per rat. Capillary density was expressed as the number per mm 2 . Only sections oriented perpendicular to the vessels were counted. Arteriolar density was counted in a similar manner.
Plasmid construction
The piggybac transposon plasmids (pXL-BSII donor plasmid) was provided by Dr Fraser at University of Notre Dame (South Bend, IN, USA) and mouse piggybac transposase helper plasmid was provided by Dr Bradley at Wellcome Trust Sanger Institute (Cambridge, England). Human TB4 cDNA was purchased from Origene technologies (Rockville, MD, USA). DsRed cDNA vector was purchased from Clontech (Mountain View, CA, USA), TB4 gene cDNAs were cloned to pCI vector (Promega, Madison, WI, USA), mouse piggybac transposase cDNA with EcoR1/NOT1 cutting also subcloned into pCI vector and then TB4 or DsRed cDNA with CMV promoter and polyA fragment with BgL II/BamH1 cutting subcloned to pXL-BSII vector. The plasmids digestion, ligation, subcloning, isolation and purification were performed by standard procedures, and once again sequenced to confirm that no artifactual mutations were present.
Manufacture of plasmid-containing lipid-stabilized microbubble Lipid-stabilized microbubbles were prepared as previously described in our laboratory. Briefly, a solution of DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine, Sigma) 2.5 mg ml 
Immunohistochemistry
The heart tissue samples were fixed in 4% paraformaldehyde and 20% sucrose for overnight at 4 1C and Cryostat sections 5-8 mm in thickness were further fixed with acetone ( À 20 1C) for 5 min and quenched for 5 min with10 mM glycine in PBS. Sections were then rinsed in PBS 3 times, and permeabilized with 0.5% Triton X-100 in PBS for 15 min. The slides that needed further nucleus protein retrieval were subjected to boiling citrate buffer solution with tween 20, pH6.0, for 5 min. Sections were blocked with 20% Aquablock solution (EastCoast Bio, North Berwick, ME) at room temperature for 1h and washed with PBS 1 time. The primary antibodies rabbit anti-WT1, 1:250 dilution, rabbit anti-NKX2.5, 1: 500 dilution, and rabbit anti-ISL-1, 1: 500 dilution, and mouse anti-cardiac troponin T, 1: 250 dilution, rabbit anti-phosopho-histone H3, 1: 500 dilution, rabbit anti-Ki-67, 1: 500 dilution, rabbit anti-BrDu, 1:250 dilution, rabbit anti-Aurora B, 1:250 dilution, mouse anti-TB4, 1:250 dilution, (Abcam Inc., Cambridge, MA, USA), donkey anti-smooth muscle a actin, 1:250 (Sigma); rabbit anti-c-kit, 1:50 dilution; rabbit anti-CD31, 1:50 dilution; rabbit anti-vascular endothelial growth factor, 1: 50 dilution, rabbit anti-TB4, 1:50 dilution (Santa Cruz biotech., Santa Cruz, CA), mouse anti-DsRed, 1: 250 dilution( Clontech) were added and incubated for 2 hrs at RT. After washing with PBS three times for 5 min, the secondary antibody (Sigma; anti-mouse lgG conjugated with FITC, anti-donkey IgG conjugated with Texas Red and anti-rabbit lgG conjugated with Cy5) (1:250 dilution in block solution) were added and incubated for 1 h at room temperature. Sections were rinsed with PBS for 10 min, three times and incubated with Dapi (Invitrogen), 1: 5000 dilution for 5 min and wash three times with phosphate-buffered saline Tween, then mounted. A confocal microscope was used to take pictures. BrdU staining included with incubating in HCl (1 N) for 10 mins on ice to break open the DNA structure of the labeled cells and then followed by HCl (2 N) for 10 mins at room temperature before moving them to an incubator for 20 mins at 37 1C. Immediately after the acid washes, Borate buffer (0.1 M) is added to buffer the cells for 12 mins.
Echocardiography
Echocardiographic measurements of LV fractional shortening and LV posterior wall thickness were made from digital images acquired with a 12 MHz broadband transducer (S12 probe, Philips Ultrasound). Fractional 
